Tellimagrandin I
Tellimagrandin I is a gap junction protein 43 (Cx43) activator, which is a hydrolyzable ellagitannin (ellagitannin) secondary metabolite extractable from various plants. Tellimagrandin I mainly restores gap junction intercellular communication (GJIC) and induces S-phase arrest in tumor cells by upregulating Cx43; activates inflammatory cells to release TNF-α and VEGF to promote angiogenesis in vivo; and protects DNA from damage via antioxidant and metal chelating effects. Tellimagrandin I can be used in research related to human cervical cancer.
For research use only. We do not sell to patients.
- CAS No.: 79786-08-6
- Formula: C34H26O22
- Molecular Weight:786.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
|
TNF-α |
Cx43 |
In Vitro
Tellimagrandin I (10-100 µM; 24 h-10 days) concentration-dependently inhibits cell growth, upregulates and restores intercellular gap junction communication, significantly upregulates Cx43 mRNA and total protein expression levels, downregulates cyclin A protein expression, markedly suppresses the colony-forming ability of cells in soft agar, induces S-phase cell cycle arrest, and correspondingly reduces the proportions of cells in G0/G1 and G2/M phases[3].
Tellimagrandin I (1-100 µg/plate; 48 h) exerts significant antimutagenic effects (protecting DNA from damage induced by 4-NQO (HY-33354) and sodium azide) in Salmonella enterica serovar Typhimurium strains (TA98, TA100)[4].
Tellimagrandin I (5-160 µM; 30 min-3 h) shows no significant cytotoxicity in human lymphocytes and exerts a DNA-protective effect when co-treated with Doxorubicin (HY-15142A)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HeLa cells
-
Concentration:20, 40, 60, 80, 100 µM
-
Incubation Time:72 h
-
Result:Inhibited cell proliferation in a concentration-dependent manner, leading to over 80% growth inhibition at 60 µM.
-
Cell Line:HeLa cells
-
Concentration:50 μM
-
Incubation Time:72 h
-
Result:Increased Cx43 mRNA levels 8.5-fold compared to the solvent control.
-
Cell Line:HeLa cells
-
Concentration:50 μM
-
Incubation Time:24, 48, 72 h
-
Result:Increased total Cx43 protein levels in a time-dependent manner, with a 7.3-fold increase after 72 h.
Restricted the increase entirely to the non-phosphorylated Cx43 (P0) form, while phosphorylated forms (P1, P2) showed no significant change.
-
Cell Line:HeLa cells
-
Concentration:10, 30, 50 µM
-
Incubation Time:10 days
-
Result:Significantly inhibited anchorage-independent growth of the cells, reducing cloning efficiency to 10% at 30 µM and leaving almost no colony formation (1.3%) at 50 µM.
-
Cell Line:HeLa cells
-
Concentration:25, 50, 75 µM
-
Incubation Time:24, 48, 72 h
-
Result:Induced S-phase cell cycle arrest in a concentration- and time-dependent manner, correspondingly decreasing the proportion of cells in G0/G1 and G2/M phases.
-
Cell Line:Human lymphocytes
-
Concentration:5, 10, 20, 40, 80, 160 µM
-
Incubation Time:3 h
-
Result:Did not induce significant cytotoxicity, and cell viability was maintained at a high level.
In Vivo
Tellimagrandin I exerts anti-tumorigenesis activity against S-180 mouse sarcoma cells in mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Gallus domesticus (fertilized eggs)[2]
-
Dosage:15 μg/μL; 30 μg/μL
-
Administration:topical application to CAM; single dose; 72 h
-
Result:Increased the area of neovascularization in the CAM model, along with increases in blood vessel length, caliber, number of junctions, and number of complexes.
Increased the number of inflammatory cells and fibroblasts in the membrane tissue, and resulted in a thickening of the membrane.
Upregulate the protein expression levels of vascular endothelial growth factor (VEGF) and tumor necrosis factor-alpha (TNF-α) in the CAM tissue.
Chemical Information
-
CAS No. 79786-08-6
-
Molecular Weight 786.56
-
Formula C34H26O22
-
SMILES
O=C(OC[C@H]1O[C@@H](O)[C@H](OC(C2=CC(O)=C(O)C(O)=C2)=O)[C@@H](OC(C3=CC(O)=C(O)C(O)=C3)=O)[C@@H]1OC(C4=CC(O)=C(O)C(O)=C45)=O)C6=C5C(O)=C(O)C(O)=C6
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[2]. Fernandes AS, et al. Pedunculagin and tellimagrandin-I stimulate inflammation and angiogenesis and upregulate vascular endothelial growth factor and tumor necrosis factor-alpha in vivo. Microvascular research. 2024 Jan;151:104615. [Content Brief]
[3]. Yi ZC, et al. Tellimagrandin I enhances gap junctional communication and attenuates the tumor phenotype of human cervical carcinoma HeLa cells in vitro. Cancer letters. 2006 Oct 08;242(1):77-87. [Content Brief]
[4]. Fernandes AS, et al. Tellimagrandin-I and camptothin a exhibit chemopreventive effects in Salmonella enterica serovar Typhimurium strains and human lymphocytes. J Toxicol Environ Health A. 2024 Mar 3;87(5):185-198. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tellimagrandin I Related Classifications
HY-N7764 Related Classifications
Powered by Bioz
Keywords
- Tellimagrandin I
- 79786-08-6
- Endogenous Metabolite
- Gap Junction Protein
- TNF Receptor
- VEGFR
- chick embryo chorioallantoic membrane
- S-phase cell cycle arrest
- Cx43
- gap junctional communication
- vascular endothelial growth factor
- tumor necrosis factor-α
- Salmonella enterica serovar Typhimurium
- human cervical carcinoma HeLa cells
- human lymphocytes
- cyclin A
- Inhibitor
- inhibitor
- inhibit